Research Fellow Position in Molecular Biology with Immunology Experience
Job Summary:
The Manstein Laboratory at Massachusetts General Hospital is conducting research in dermatology, focusing on the development of novel, energy-based procedures for the treatment of various skin conditions, including scars, burns, aging skin, and fat removal. We are inviting applications for a dedicated and innovative Research Fellow with a strong foundation in Molecular Biology and Immunology. This position requires the successful candidate to contribute to our ongoing projects by designing and executing experiments, analyzing complex data sets, and publishing findings through scientific communication. The role requires expertise in molecular biology and immunology techniques to be applied in a dermatological context.
Responsibilities:
Requirements:
Preferred Qualifications:
Position Details:
This is a full-time role offering a competitive salary (above NIH post doc stipend levels) and benefits package, matching experience, and qualifications. Located within the research community of Massachusetts General Hospital - Harvard Medical School, the Manstein Lab provides an exceptional environment for scientific growth and discovery.
If you are passionate about molecular biology and immunology within dermatology and eager to contribute to developing innovative medical solutions, please submit your application. Include your resume and a cover letter highlighting your relevant experience and interests.
Applications will be reviewed on a rolling basis until the position is filled. We thank all applicants for their interest; however, only those selected for an interview will be contacted.
Project Description:
Building upon the foundational insights gained from exploring immune checkpoint inhibitors (ICIs) and the novel use of ablative fractional photothermolysis (aFP) in oncology, our next project seeks to unify and expand upon these strategies to address the challenge of neoantigen-deficiency in cancer treatment. By integrating the mechanisms through which ICIs leverage the immune system's ability to recognize and combat tumor-specific neoantigens with the potentiation of immune responses observed with aFP, combined with immune modulators such as anti-PD-1 antibodies and OX40 agonists, we aim to create a comprehensive approach that induces robust anti-tumor immunity across a broader spectrum of cancer types. This project will explore the synergy between these modalities to promote epitope spreading and enhance the immunogenicity of tumors traditionally considered non-responsive to current immunotherapies. Through detailed molecular and cellular analyses, alongside innovative in vivo models, we will investigate the potential for this combined therapy to generate tumor remissions, even in the absence of high neoantigen burdens, by fostering an immune environment that supports the development of memory responses against tumor-lineage self-antigens. This research represents a significant step towards developing universal strategies for cancer immunotherapy, potentially transforming the treatment landscape for patients with neoantigen-deficient malignancies.
Previous Publications:
https://www.science.org/doi/10.1126/scitranslmed.abd8636
https://www.biorxiv.org/content/10.1101/2021.11.29.470433v3
Preferred Qualifications: